


Newspaper Publication of Q2 FY 2020-21 Result
Glenmark’s Q2 FY 2020-21 Results
Glenmark’s MDA Q2 FY 2020 – 21
Glenmark’s consolidated revenue increased by 4.88 % to Rs. 29,524.79 mn for Q2 FY 2020-21
Chairman’s Speech at the 42nd AGM
Proceedings and Scrutinizer's Report of the 42nd AGM
Know More
Glenmark Pharmaceuticals receives ANDA final approval for Tadalafil Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg; and receives ANDA tentative approvals for Gabapentin Enacarbil Extended-Release Tablets, 300 mg and 600 mg and Apremilast Tablets, 10 mg, 20 mg and 30 mg
Know MoreGlenmark is a leading, research–based global pharmaceutical company
Know More


X
This website uses cookies. By continuing to browse the site you are agreeing to our use of cookies. For more details refer to our Terms of Use Policy.